Sugi Predict

Sugi Predict / Compounds / SCHEMBL484826

SCHEMBL484826

SCHEMBL484826

O=C(O)N1CCC2(CCNCC2)C1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.49
▸ CYP2D6 P10635 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ GABRD O14764 2/20 0.45
▸ GABRA1 P14867 2/20 0.45
▸ GABRB1 P18505 2/20 0.45
▸ GABRA5 P31644 2/20 0.45
▸ GABRA3 P34903 2/20 0.45
▸ GABRA2 P47869 2/20 0.45
▸ GABRB2 P47870 2/20 0.45
▸ GABRA4 P48169 2/20 0.45
▸ NAMPT P43490 1/20 0.42
▸ KDM1A O60341 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ RCOR1 Q9UKL0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3353242 0.89 CYP3A4 (0.58) CYP1A2CYP2D6CYP3A4NAMPT
SCHEMBL27036544 0.89 HSD17B10 (0.49) CYP1A2CYP2D6CYP3A4GABRDGABRA1
SCHEMBL27227211 0.89 HSD17B10 (0.49) CYP1A2CYP2D6CYP3A4GABRDGABRA1
SCHEMBL484820 0.89 HSD17B10 (0.49) CYP1A2CYP2D6CYP3A4GABRDGABRA1
SCHEMBL485154 0.88 CYP1A2 (0.56) CYP1A2CYP2D6GABRDGABRA1GABRB1
Hydrochloric Acid SCHEMBL2074181 0.86 CYP1A2 (0.54) CYP1A2CYP2D6GABRDGABRA1GABRB1
SCHEMBL2439391 0.85 CYP1A2 (0.43) CYP1A2CYP2D6CYP3A4GABRDGABRA1
SCHEMBL29418104 0.85 HSD11B1 (0.42) CYP3A4
Hydrochloric Acid SCHEMBL2434750 0.83 CYP1A2 (0.42) CYP1A2CYP2D6CYP3A4GABRDGABRA1
SCHEMBL8170293 0.82 CYP1A2 (0.51) CYP1A2CYP2D6CYP3A4GABRDGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3723754-B1 IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME LLC (US) 2026-05-13 — — EP claimed
US-12344623-B2 Thiazolopyridine derivatives as adenosine receptor antagonists DOMAIN THERAPEUTICS SA (FR) 2025-07-01 — — US claimed
EP-3307067-B1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME LLC (US) 2022-11-02 — — EP claimed
US-20220119412-A1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-04-21 — — US claimed
US-12624053-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2026-05-12 — — US disclosed
US-20260070930-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2026-03-12 — — US disclosed
US-20250388608-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-12-25 — — US disclosed
US-12344623-B2 Thiazolopyridine derivatives as adenosine receptor antagonists DOMAIN THERAPEUTICS SA (FR) 2025-07-01 — — US disclosed
US-20250197423-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-06-19 — — US disclosed
WO-2025106482-A1 COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) 2025-05-22 — — WO disclosed
US-20250145643-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-05-08 — — US disclosed
CN-119798279-A RAS inhibitors 锐新医药公司 2025-04-11 — — CN disclosed
WO-2010089127-A1 SUBSTITUTED SPIRO-AMIDES AS B1R MODULATORS Grünenthal GmbH (DE) 2010-08-12 — — WO disclosed
WO-2010089084-A1 SUBSTITUTED INDOLE COMPOUNDS AS BRADYKININ RECEPTOR 1 MODULATORS Grünenthal GmbH (DE) 2010-08-12 — — WO disclosed
US-20100152158-A1 Substituted Disulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-06-17 — — US disclosed
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 — — EP disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 — — US disclosed
WO-2007140383-A2 SPIROCYCLIC SULFONAMIDES AND RELATED COMPOUNDS NEUROGEN CORPORATION (US) 2007-12-06 — — WO disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 — — WO disclosed
WO-2000027790-A1 MUTILIN COMPOUNDS SMITHKLINE BEECHAM P.L.C. (GB) 2000-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070930-A1 RAS INHIBITORS KRAS, NRAS, RIN1 CYP1A2 2007/4885CYP2D6 815/4885CYP3A4 1715/4885
US-20250145643-A1 RAS INHIBITORS KRAS, NRAS, HRAS CYP1A2 4576/4885CYP2D6 3178/4885CYP3A4 3780/4885
US-20100152158-A1 Substituted Disulfonamide Compounds BDKRB1, BDKRB2, BRS3 CYP1A2 2757/4885CYP2D6 1247/4885CYP3A4 2223/4885
US-12344623-B2 Thiazolopyridine derivatives as adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 CYP1A2 1318/4885CYP2D6 1794/4885CYP3A4 2269/4885
US-12624053-B2 Ras inhibitors KRAS, NRAS, HMGCR CYP1A2 1927/4885CYP2D6 592/4885CYP3A4 824/4885
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 CYP1A2 1043/4885CYP2D6 1049/4885CYP3A4 1450/4885
US-20250197423-A1 RAS INHIBITORS KRAS, NRAS, HRAS CYP1A2 4576/4885CYP2D6 3178/4885CYP3A4 3780/4885
US-20250388608-A1 RAS INHIBITORS KRAS, NRAS, HMGCR CYP1A2 1927/4885CYP2D6 592/4885CYP3A4 824/4885
US-20220119412-A1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 CYP1A2 1318/4885CYP2D6 1794/4885CYP3A4 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.